Chung enjoys the challenges of genetics as a rapidly changing field of medicine and strives to facilitate the integration of genetic medicine into all areas of health care in a medically, scientifically, and ethically sound, accessible, and cost-effective manner.Ĭatherine Cottrell, PhD, FACMG serves as a Senior Director of the Institute for Genomic Medicine Clinical Laboratory at Nationwide Children’s Hospital. She was the recipient of the Medical Achievement Award from Bonei Olam, the New York Academy of Medicine Medal for Distinguished Contributions in Biomedical Science, and the Rare Impact Award from the National Organization for Rare Disorders and is a member of the National Academy of Medicine and the American Academy of Physicians. Chung has authored more than 500 peer-reviewed papers and 75 reviews and chapters in medical texts. She leads the Precision Medicine Resource in the Irving Institute for Clinical and Translational Research at Columbia University.ĭr. She is a national leader in the ethical, legal, and social implications of genomics. Chung directs NIH-funded research programs in human genetics of pulmonary hypertension, autism, and birth defects, including congenital diaphragmatic hernia and congenital heart disease. in genetics from The Rockefeller University.ĭr.
from Cornell University Medical College, and her Ph.D. in biochemistry and economics from Cornell University, her M.D. Wendy Chung, M.D., Ph.D. is a clinical and molecular geneticist and the Kennedy Family Professor of Pediatrics and Medicine and director of clinical genetics at Columbia University. We aim to pass the torch from pioneering researchers and developers of genome technologies to first movers in healthcare who are establishing standards of care and cutting-edge applications for genome technology in everyday clinical practice. We bring together practitioners and innovators at the interface of genomics, medicine, and health to usher in a new era of precision medicine. This event is for leading genomic researchers, healthcare professionals, and healthcare industry stakeholders. Continuing the historical focus of AGBT on technologies and public-private partnerships, the Precision Health Meeting highlights innovative technologies and their impact on clinical diagnostics and therapeutic development, as well as the evolving view of genotype-phenotype interpretation from rare variants to polygenic risk scores. Over the last several years, this meeting has highlighted the most provocative discoveries and major initiatives in genomic medicine from leaders of national healthcare systems, genomics institutes, international biobank initiatives, transformative diagnostic approaches, and hospital-based implementation and reimbursement.
0 kommentar(er)
